Sitagliptin Improves Glycemic Profile In Type 2 Diabetes Mild Renal Impairment | Latest News RSS feed
Sitagliptin Improves Glycemic Profile In Type 2 Diabetes Mild Renal Impairment - Latest News
Dipeptidyl Peptidase-IV Inhibitors: Pharmacological Profile and Clinical Use
People with type 2 diabetes have reduced circulating levels of GLP-1 but retain their ability to respond to this hormone. Thus, it is possible to improve glycemic control ... with moderate to severe r... read more
Merck Presents New Data from the Comparative Trials with Sitagliptin (CompoSIT) Clinical Trial Program with JANUVIA® (sitagliptin)
“These studies further support the clinical profile of JANUVIA ... Safety and Efficacy of Sitagliptin Compared with Dapagliflozin in Subjects with Type 2 Diabetes, Mild Renal Impairment and Inadequate ... read more
Lexicon Pharmaceuticals' CEO Discusses Q2 2013 Results - Earnings Call Transcript
The first that I’ll be reviewing with you is the 30-patient study of LX4211 in patients with type 2 diabetes and renal impairment ... I’ll show you are well below the doses required to improve glycemi... read more
Looking for another news?
Current Therapeutic Drugs for Type 2 Diabetes, Still Useful After 50 Years?
The primary aim of managing Type 2 diabetes is to delay, or even prevent, the complications of the disease by achieving good glycemic control ... moderate renal impairment (with a reduced dose), and m... read more
The Role of α-Cell Dysregulation in Fasting and Postprandial Hyperglycemia in Type 2 Diabetes and Therapeutic Implications
Studies utilizing these tools to establish the function of glucagon in normal nutrient homeostasis and to document a relative glucagon excess in type 2 diabetes ... importance of α-cell dysregulation ... read more
Elcelyx 'Guts' Conventional Thinking on Metformin
The company plans to initiate a pharmacokinetic study this summer in Type II diabetes patients with mild, moderate and severe renal impairment ... 2 inhibitor, provided greater improvements in blood g... read more
FDA Advisory Committee Recommends the Investigational SGLT2 Inhibitor Dapagliflozin for the Treatment of Type 2 Diabetes in Adults
Dapagliflozin is being reviewed by the FDA for use as monotherapy, and in combination with other antidiabetic agents, as an adjunct to diet and exercise to improve glycemic control in adults with type ... read more
The Ideal Diabetes Therapy: What Will It Look Like? How Close Are We?
Today, 11 classes of diabetes drugs are available, and many more are in development. Despite this increase, diabetes was the leading cause of blindness, kidney failure ... effective long-term glycemic ... read more
Ozempic® approved in Canada for the treatment of adults with type 2 diabetes
as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, when metformin is not tolerated or contraindicated. 1 Ozempic ®, a once-weekly glucagon-like pep... read more
Lexicon Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call Transcript
In addition to this we’ve initiated a proof-of-concept study and type 2 diabetes patients who have moderate to severe renal impairment ... like in the mild studies we see a synergistic elevation of ac... read more